Non-dystrophic myotonia: Prospective study of objective and patient reported outcomes

Jaya R. Trivedi, Brian Bundy, Jeffrey Statland, Mohammad Salajegheh, Dipa Raja Rayan, Shannon L. Venance, Yunxia Wang, Doreen Fialho, Emma Matthews, James Cleland, Nina Gorham, Laura Herbelin, Stephen Cannon, Anthony Amato, Robert C. Griggs, Michael G. Hanna, Richard J. Barohn

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

Non-dystrophic myotonias are rare diseases caused by mutations in skeletal muscle chloride and sodium ion channels with considerable phenotypic overlap between diseases. Few prospective studies have evaluated the sensitivity of symptoms and signs of myotonia in a large cohort of patients. We performed a prospective observational study of 95 participants with definite or clinically suspected non-dystrophic myotonia recruited from six sites in the USA, UK and Canada between March 2006 and March 2009. We used the common infrastructure and data elements provided by the NIH-funded Rare Disease Clinical Research Network. Outcomes included a standardized symptom interview and physical exam; the Short Form-36 and the Individualized Neuromuscular Quality of Life instruments; electrophysiological short and prolonged exercise tests; manual muscle testing; and a modified get-up-and-go test. Thirty-two participants had chloride channel mutations, 34 had sodium channel mutations, nine had myotonic dystrophy type 2, one had myotonic dystrophy type 1, and 17 had no identified mutation. Phenotype comparisons were restricted to those with sodium channel mutations, chloride channel mutations, and myotonic dystrophy type 2. Muscle stiffness was the most prominent symptom overall, seen in 66.7% to 100% of participants. In comparison with chloride channel mutations, participants with sodium mutations had an earlier age of onset of stiffness (5 years versus 10 years), frequent eye closure myotonia (73.5% versus 25%), more impairment on the Individualized Neuromuscular Quality of Life summary score (20.0 versus 9.44), and paradoxical eye closure myotonia (50% versus 0%). Handgrip myotonia was seen in three-quarters of participants, with warm up of myotonia in 75% chloride channel mutations, but also 35.3% of sodium channel mutations. The short exercise test showed 10% decrement in the compound muscle action potential amplitude in 59.3% of chloride channel participants compared with 27.6% of sodium channel participants, which increased post-cooling to 57.6% in sodium channel mutations. In evaluation of patients with clinical and electrical myotonia, despite considerable phenotypic overlap, the presence of eye closure myotonia, paradoxical myotonia, and an increase in short exercise test sensitivity post-cooling suggest sodium channel mutations. Outcomes designed to measure stiffness or the electrophysiological correlates of stiffness may prove useful for future clinical trials, regardless of underlying mutation, and include patient-reported stiffness, bedside manoeuvres to evaluate myotonia, muscle specific quality of life instruments and short exercise testing.

Original languageEnglish (US)
Pages (from-to)2189-2200
Number of pages12
JournalBrain
Volume136
Issue number7
DOIs
StatePublished - Jul 2013

Fingerprint

Myotonia
Prospective Studies
Sodium Channels
Mutation
Chloride Channels
Myotonic Dystrophy
Exercise Test
Muscles
Quality of Life
Rare Diseases
Patient Reported Outcome Measures
Age of Onset

Keywords

  • CLCN1
  • myotonia
  • non-dystrophic myotonia
  • paramyotonia
  • SCN4A

ASJC Scopus subject areas

  • Clinical Neurology
  • Arts and Humanities (miscellaneous)

Cite this

Trivedi, J. R., Bundy, B., Statland, J., Salajegheh, M., Rayan, D. R., Venance, S. L., ... Barohn, R. J. (2013). Non-dystrophic myotonia: Prospective study of objective and patient reported outcomes. Brain, 136(7), 2189-2200. https://doi.org/10.1093/brain/awt133

Non-dystrophic myotonia : Prospective study of objective and patient reported outcomes. / Trivedi, Jaya R.; Bundy, Brian; Statland, Jeffrey; Salajegheh, Mohammad; Rayan, Dipa Raja; Venance, Shannon L.; Wang, Yunxia; Fialho, Doreen; Matthews, Emma; Cleland, James; Gorham, Nina; Herbelin, Laura; Cannon, Stephen; Amato, Anthony; Griggs, Robert C.; Hanna, Michael G.; Barohn, Richard J.

In: Brain, Vol. 136, No. 7, 07.2013, p. 2189-2200.

Research output: Contribution to journalArticle

Trivedi, JR, Bundy, B, Statland, J, Salajegheh, M, Rayan, DR, Venance, SL, Wang, Y, Fialho, D, Matthews, E, Cleland, J, Gorham, N, Herbelin, L, Cannon, S, Amato, A, Griggs, RC, Hanna, MG & Barohn, RJ 2013, 'Non-dystrophic myotonia: Prospective study of objective and patient reported outcomes', Brain, vol. 136, no. 7, pp. 2189-2200. https://doi.org/10.1093/brain/awt133
Trivedi JR, Bundy B, Statland J, Salajegheh M, Rayan DR, Venance SL et al. Non-dystrophic myotonia: Prospective study of objective and patient reported outcomes. Brain. 2013 Jul;136(7):2189-2200. https://doi.org/10.1093/brain/awt133
Trivedi, Jaya R. ; Bundy, Brian ; Statland, Jeffrey ; Salajegheh, Mohammad ; Rayan, Dipa Raja ; Venance, Shannon L. ; Wang, Yunxia ; Fialho, Doreen ; Matthews, Emma ; Cleland, James ; Gorham, Nina ; Herbelin, Laura ; Cannon, Stephen ; Amato, Anthony ; Griggs, Robert C. ; Hanna, Michael G. ; Barohn, Richard J. / Non-dystrophic myotonia : Prospective study of objective and patient reported outcomes. In: Brain. 2013 ; Vol. 136, No. 7. pp. 2189-2200.
@article{17308c546f9f4fab9617da83b516083f,
title = "Non-dystrophic myotonia: Prospective study of objective and patient reported outcomes",
abstract = "Non-dystrophic myotonias are rare diseases caused by mutations in skeletal muscle chloride and sodium ion channels with considerable phenotypic overlap between diseases. Few prospective studies have evaluated the sensitivity of symptoms and signs of myotonia in a large cohort of patients. We performed a prospective observational study of 95 participants with definite or clinically suspected non-dystrophic myotonia recruited from six sites in the USA, UK and Canada between March 2006 and March 2009. We used the common infrastructure and data elements provided by the NIH-funded Rare Disease Clinical Research Network. Outcomes included a standardized symptom interview and physical exam; the Short Form-36 and the Individualized Neuromuscular Quality of Life instruments; electrophysiological short and prolonged exercise tests; manual muscle testing; and a modified get-up-and-go test. Thirty-two participants had chloride channel mutations, 34 had sodium channel mutations, nine had myotonic dystrophy type 2, one had myotonic dystrophy type 1, and 17 had no identified mutation. Phenotype comparisons were restricted to those with sodium channel mutations, chloride channel mutations, and myotonic dystrophy type 2. Muscle stiffness was the most prominent symptom overall, seen in 66.7{\%} to 100{\%} of participants. In comparison with chloride channel mutations, participants with sodium mutations had an earlier age of onset of stiffness (5 years versus 10 years), frequent eye closure myotonia (73.5{\%} versus 25{\%}), more impairment on the Individualized Neuromuscular Quality of Life summary score (20.0 versus 9.44), and paradoxical eye closure myotonia (50{\%} versus 0{\%}). Handgrip myotonia was seen in three-quarters of participants, with warm up of myotonia in 75{\%} chloride channel mutations, but also 35.3{\%} of sodium channel mutations. The short exercise test showed 10{\%} decrement in the compound muscle action potential amplitude in 59.3{\%} of chloride channel participants compared with 27.6{\%} of sodium channel participants, which increased post-cooling to 57.6{\%} in sodium channel mutations. In evaluation of patients with clinical and electrical myotonia, despite considerable phenotypic overlap, the presence of eye closure myotonia, paradoxical myotonia, and an increase in short exercise test sensitivity post-cooling suggest sodium channel mutations. Outcomes designed to measure stiffness or the electrophysiological correlates of stiffness may prove useful for future clinical trials, regardless of underlying mutation, and include patient-reported stiffness, bedside manoeuvres to evaluate myotonia, muscle specific quality of life instruments and short exercise testing.",
keywords = "CLCN1, myotonia, non-dystrophic myotonia, paramyotonia, SCN4A",
author = "Trivedi, {Jaya R.} and Brian Bundy and Jeffrey Statland and Mohammad Salajegheh and Rayan, {Dipa Raja} and Venance, {Shannon L.} and Yunxia Wang and Doreen Fialho and Emma Matthews and James Cleland and Nina Gorham and Laura Herbelin and Stephen Cannon and Anthony Amato and Griggs, {Robert C.} and Hanna, {Michael G.} and Barohn, {Richard J.}",
year = "2013",
month = "7",
doi = "10.1093/brain/awt133",
language = "English (US)",
volume = "136",
pages = "2189--2200",
journal = "Brain",
issn = "0006-8950",
publisher = "Oxford University Press",
number = "7",

}

TY - JOUR

T1 - Non-dystrophic myotonia

T2 - Prospective study of objective and patient reported outcomes

AU - Trivedi, Jaya R.

AU - Bundy, Brian

AU - Statland, Jeffrey

AU - Salajegheh, Mohammad

AU - Rayan, Dipa Raja

AU - Venance, Shannon L.

AU - Wang, Yunxia

AU - Fialho, Doreen

AU - Matthews, Emma

AU - Cleland, James

AU - Gorham, Nina

AU - Herbelin, Laura

AU - Cannon, Stephen

AU - Amato, Anthony

AU - Griggs, Robert C.

AU - Hanna, Michael G.

AU - Barohn, Richard J.

PY - 2013/7

Y1 - 2013/7

N2 - Non-dystrophic myotonias are rare diseases caused by mutations in skeletal muscle chloride and sodium ion channels with considerable phenotypic overlap between diseases. Few prospective studies have evaluated the sensitivity of symptoms and signs of myotonia in a large cohort of patients. We performed a prospective observational study of 95 participants with definite or clinically suspected non-dystrophic myotonia recruited from six sites in the USA, UK and Canada between March 2006 and March 2009. We used the common infrastructure and data elements provided by the NIH-funded Rare Disease Clinical Research Network. Outcomes included a standardized symptom interview and physical exam; the Short Form-36 and the Individualized Neuromuscular Quality of Life instruments; electrophysiological short and prolonged exercise tests; manual muscle testing; and a modified get-up-and-go test. Thirty-two participants had chloride channel mutations, 34 had sodium channel mutations, nine had myotonic dystrophy type 2, one had myotonic dystrophy type 1, and 17 had no identified mutation. Phenotype comparisons were restricted to those with sodium channel mutations, chloride channel mutations, and myotonic dystrophy type 2. Muscle stiffness was the most prominent symptom overall, seen in 66.7% to 100% of participants. In comparison with chloride channel mutations, participants with sodium mutations had an earlier age of onset of stiffness (5 years versus 10 years), frequent eye closure myotonia (73.5% versus 25%), more impairment on the Individualized Neuromuscular Quality of Life summary score (20.0 versus 9.44), and paradoxical eye closure myotonia (50% versus 0%). Handgrip myotonia was seen in three-quarters of participants, with warm up of myotonia in 75% chloride channel mutations, but also 35.3% of sodium channel mutations. The short exercise test showed 10% decrement in the compound muscle action potential amplitude in 59.3% of chloride channel participants compared with 27.6% of sodium channel participants, which increased post-cooling to 57.6% in sodium channel mutations. In evaluation of patients with clinical and electrical myotonia, despite considerable phenotypic overlap, the presence of eye closure myotonia, paradoxical myotonia, and an increase in short exercise test sensitivity post-cooling suggest sodium channel mutations. Outcomes designed to measure stiffness or the electrophysiological correlates of stiffness may prove useful for future clinical trials, regardless of underlying mutation, and include patient-reported stiffness, bedside manoeuvres to evaluate myotonia, muscle specific quality of life instruments and short exercise testing.

AB - Non-dystrophic myotonias are rare diseases caused by mutations in skeletal muscle chloride and sodium ion channels with considerable phenotypic overlap between diseases. Few prospective studies have evaluated the sensitivity of symptoms and signs of myotonia in a large cohort of patients. We performed a prospective observational study of 95 participants with definite or clinically suspected non-dystrophic myotonia recruited from six sites in the USA, UK and Canada between March 2006 and March 2009. We used the common infrastructure and data elements provided by the NIH-funded Rare Disease Clinical Research Network. Outcomes included a standardized symptom interview and physical exam; the Short Form-36 and the Individualized Neuromuscular Quality of Life instruments; electrophysiological short and prolonged exercise tests; manual muscle testing; and a modified get-up-and-go test. Thirty-two participants had chloride channel mutations, 34 had sodium channel mutations, nine had myotonic dystrophy type 2, one had myotonic dystrophy type 1, and 17 had no identified mutation. Phenotype comparisons were restricted to those with sodium channel mutations, chloride channel mutations, and myotonic dystrophy type 2. Muscle stiffness was the most prominent symptom overall, seen in 66.7% to 100% of participants. In comparison with chloride channel mutations, participants with sodium mutations had an earlier age of onset of stiffness (5 years versus 10 years), frequent eye closure myotonia (73.5% versus 25%), more impairment on the Individualized Neuromuscular Quality of Life summary score (20.0 versus 9.44), and paradoxical eye closure myotonia (50% versus 0%). Handgrip myotonia was seen in three-quarters of participants, with warm up of myotonia in 75% chloride channel mutations, but also 35.3% of sodium channel mutations. The short exercise test showed 10% decrement in the compound muscle action potential amplitude in 59.3% of chloride channel participants compared with 27.6% of sodium channel participants, which increased post-cooling to 57.6% in sodium channel mutations. In evaluation of patients with clinical and electrical myotonia, despite considerable phenotypic overlap, the presence of eye closure myotonia, paradoxical myotonia, and an increase in short exercise test sensitivity post-cooling suggest sodium channel mutations. Outcomes designed to measure stiffness or the electrophysiological correlates of stiffness may prove useful for future clinical trials, regardless of underlying mutation, and include patient-reported stiffness, bedside manoeuvres to evaluate myotonia, muscle specific quality of life instruments and short exercise testing.

KW - CLCN1

KW - myotonia

KW - non-dystrophic myotonia

KW - paramyotonia

KW - SCN4A

UR - http://www.scopus.com/inward/record.url?scp=84879958015&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84879958015&partnerID=8YFLogxK

U2 - 10.1093/brain/awt133

DO - 10.1093/brain/awt133

M3 - Article

C2 - 23771340

AN - SCOPUS:84879958015

VL - 136

SP - 2189

EP - 2200

JO - Brain

JF - Brain

SN - 0006-8950

IS - 7

ER -